依托咪酯与氯胺酮用于院内快速序贯插管:系统评价与Meta分析
该系统评价与Meta分析检索截至2024年11月1日的多个数据库及临床试验注册平台,纳入14项研究共23926例患者(依托咪酯19288例,氯胺酮4638例),比较两种诱导剂用于院内快速序贯插管的效果。主要终点30天生存率在随机对照试验(OR=0.92,95%CI 0.68-1.24,P=0.58)和对照临床试验(OR=1.16,95%CI 0.92-1.45,P=0.58)中均无显著差异。氯胺酮组插管后血管加压药支持需求更高(OR=0.71,95%CI 0.53-0.96,P=0.03),且无ICU天数增加;依托咪酯组肾上腺功能不全发生率显著更高(OR=2.43,95%CI 1.67-3.53,P<0.001)。插管困难、心血管崩溃及全身激素使用两组无显著差异。
要点
- 在危重症患者院内快速序贯插管中,依托咪酯与氯胺酮的30天生存率无显著差异(随机对照试验OR=0.92,95%CI 0.68-1.24,P=0.58;对照临床试验OR=1.16,95%CI 0.92-1.45,P=0.58)。
- 依托咪酯组肾上腺功能不全发生率显著高于氯胺酮组(OR=2.43,95%CI 1.67-3.53,P<0.001)。
- 氯胺酮组插管后血管加压药支持需求更高(OR=0.71,95%CI 0.53-0.96,P=0.03),且无ICU天数增加。
- 插管困难、心血管崩溃及全身激素使用两组无显著差异。
- 该Meta分析纳入14项研究共23926例患者(依托咪酯19288例,氯胺酮4638例)。
适用人群与场景
- 接受院内快速序贯插管的危重症患者,纳入随机对照试验和对照临床试验。
研究设计与关键结果
- 研究类型为系统评价与Meta分析,纳入14项研究共23926例患者(依托咪酯19288例,氯胺酮4638例)。
- 主要终点30天生存率:随机对照试验OR=0.92(95%CI 0.68-1.24,P=0.58),对照临床试验OR=1.16(95%CI 0.92-1.45,P=0.58),两组均无显著差异。
- 氯胺酮组插管后血管加压药支持需求更高(OR=0.71,95%CI 0.53-0.96,P=0.03),且无ICU天数增加。
- 依托咪酯组肾上腺功能不全发生率显著更高(OR=2.43,95%CI 1.67-3.53,P<0.001)。
- 插管困难、心血管崩溃及全身激素使用两组无显著差异。
证据类型、等级与局限
- 证据类型为系统评价与Meta分析,纳入随机对照试验和对照临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在危重症患者院内快速序贯插管选择诱导剂时,依托咪酯与氯胺酮的30天生存率无显著差异。
- 选择依托咪酯时需注意其与肾上腺功能不全发生率更高相关(OR=2.43,95%CI 1.67-3.53,P<0.001)。
- 选择氯胺酮时需注意插管后血管加压药支持需求更高(OR=0.71,95%CI 0.53-0.96,P=0.03)。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rapid sequence intubation (RSI) is a critical procedure in emergency and intensive care settings. Etomidate has been favored for its hemodynamic stability; however, concerns about adrenal insufficiency have prompted interest in ketamine as an alternative induction agent. This systematic review and meta-analysis aimed to compare the effects of etomidate vs ketamine on 30-day survival and other clinical outcomes in critically ill patients undergoing in-hospital RSI. A comprehensive literature search was conducted until 1 November 2024, across PubMed, Embase, Web of Science, Cochrane databases, and clinical trial registries. Eligible studies included randomized controlled trials (RCTs) and controlled clinical trials (CCTs) assessing etomidate vs ketamine for RSI. The primary outcome was 30-day survival. Secondary outcomes encompassed intubation difficulty, post-intubation vasopressor use, cardiovascular collapse, Sequential Organ Failure Assessment score, systemic steroid use, organ support-free days, and adrenal insufficiency. Fourteen studies comprising 23 926 patients (19 288 receiving etomidate; 4638 receiving ketamine) met the inclusion criteria. Pooled analyses of RCTs and CCTs revealed no significant difference in 30-day survival between the two agents [RCTs: odds ratio (OR) = 0.92, 95% confidence interval (CI): 0.68-1.24, P = 0.58; CCTs: OR = 1.16, 95% CI: 0.92-1.45, P = 0.58]. Ketamine was associated with a higher requirement for post-intubation vasopressor support (OR = 0.71, 95% CI: 0.53-0.96, P = 0.03) and an increase in ICU-free days. Etomidate use correlated with a significantly higher incidence of adrenal insufficiency (OR = 2.43, 95% CI: 1.67-3.53, P < 0.001). No significant differences were observed in intubation difficulty, cardiovascular collapse, or systemic steroid use between the groups. Ketamine and etomidate showed no significant difference in 30-day survival among critically ill patients undergoing RSI. However, etomidate was associated with a higher incidence of adrenal insufficiency, while ketamine required more post-intubation vasopressor support. Provenance and peer review: Not commissioned, externally peer-reviewed.
参考来源
- Daghmouri MA, Chaouch MA, Noomen M, et al. Etomidate versus ketamine for in-hospital rapid sequence intubation: a systematic review and meta-analysis. Eur J Emerg Med. 2025. PMID: 40239104. doi:10.1097/MEJ.0000000000001237
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。